



ASX Announcement

15 November 2022

Appointment of Independent Non-executive Director

Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) is delighted to announce the appointment of Dr Cheri Walker as an independent Non-Executive Director.

Based in the US, Dr Walker brings more than two decades of experience working in life science tools and medical diagnostics with companies ranging from startups to global businesses. Dr Walker is currently engaged by Rhinostics Inc as President and Chief Executive Officer. She has held various operating and corporate development roles at bell weather companies, including Invitrogen, QIAGEN, Charles River Laboratories, and most recently as senior vice president of corporate development at Abcam. Dr Walker has significant health industry commercialisation experience, holding the position of Chief Financial Officer at Kailos Genetics, currently serves a director for Cell IDx, and consulting with many early-stage companies. Dr Walker began her career as a stock analyst with Deutsche Bank, covering life science tools companies.

Dr. Walker holds a PhD in Human and Molecular Genetics from Baylor College of Medicine and a BA in Biology from Swarthmore College.

Atomo's Chair, John Keith said, "we are delighted to welcome Dr Walker to the Board. Her extensive experience across life sciences and medical diagnostics complement and deepen the Board's collective skills."

For more information:

John Kelly

MD & CEO, Atomo Diagnostics Limited

john.kelly@atomodiagnostics.com

+61 401 922 279

This announcement was authorised by the Board of Atomo Diagnostics Limited.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at www.atomodiagnostics.com